Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma

A. Kessinger, A. Nademanee, S. J. Forman, J. O. Armitage

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Modern high-dose therapy with autologous bone marrow transplantation (ABMT) used for the management of Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) began about a decade ago. ABMT may avoid the problems of findings a suitable donor for transplantation and graft-versus-host disease while eradicating a disease or providing long-term, disease-free survival to patients. Outcome depends on the grade of the disease. Efforts to reduce the morbidity and mortality associated with high-dose therapy, to identify the optimal high-dose therapy for each histologic type of lymphoma, and to better identify those patients most likely to benefit continue.

Original languageEnglish (US)
Pages (from-to)577-587
Number of pages11
JournalHematology/Oncology Clinics of North America
Issue number3
StatePublished - Jun 1 1990

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this